Advanced Cell Technology to Host Conference Call and Webcast to Provide a Corporate Update for the Third Quarter of 2014

MARLBOROUGH, Mass.--()--Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the company will host a conference call on Monday, November 10, 2014 at 4:30 p.m. EST during which it will provide a corporate update for the third quarter of 2014.

Interested parties may access the call live by dialing (888) 264-3177 and using conference ID 87191640.

This event is also being streamed via webcast. The webcast is available at http://engage.vevent.com/rt/act~advancedcelltechnology111014. A replay of the call will also be available via the same link for 90 days.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a Marlborough, Mass.-based biotechnology company focused on the development and commercialization of novel cell-based therapies. ACT’s therapeutic area of focus is ophthalmology and the Company’s most advanced products are in clinical trials for the treatment of dry age-related macular degeneration, Stargardt’s macular degeneration and myopic macular degeneration. The Company is also developing several pre-clinical cell therapies for the treatment of other ocular disorders. Additionally, the Company also has a number of pre-clinical stage assets in disease areas outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders. For more information, visit www.advancedcell.com

Contacts

Contact:
Investors:
Westwicke Partners
John Woolford, 443-213-0506
or
Press:
Russo Partners
David Schull, 858-717-2310

Advanced Cell Technology, Inc.